Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FSTX

F-star Therapeutics (FSTX) Stock Price, News & Analysis

F-star Therapeutics logo

About F-star Therapeutics Stock (NASDAQ:FSTX)

Key Stats

Today's Range
$7.12
$7.12
50-Day Range
$4.42
$7.12
52-Week Range
$2.07
$7.12
Volume
N/A
Average Volume
709,213 shs
Market Capitalization
$156.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

Receive FSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FSTX Stock News Headlines

Astria Therapeutics price target raised to $28 from $26 at Oppenheimer
Lake Street Remains a Buy on Aquestive Therapeutics (AQST)
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Bicara Therapeutics Rises 39% in Debut on Nasdaq
See More Headlines

FSTX Stock Analysis - Frequently Asked Questions

F-star Therapeutics, Inc. (NASDAQ:FSTX) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.06. The company had revenue of $0.75 million for the quarter, compared to analysts' expectations of $7.18 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that F-star Therapeutics investors own include New Age Brands (NF), Aurora Cannabis (ACB), Trican Well Service (TCW), Meta Platforms (META), NIO (NIO), Plug Power (PLUG) and Copper Mountain Mining (CMMC).

Company Calendar

Last Earnings
11/10/2021
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FSTX
Employees
84
Year Founded
N/A

Profitability

Net Income
$-31,280,000.00
Pretax Margin
-213.97%

Debt

Sales & Book Value

Annual Sales
$21.17 million
Book Value
$4.70 per share

Miscellaneous

Free Float
21,279,000
Market Cap
$156.50 million
Optionable
Not Optionable
Beta
0.85
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:FSTX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners